[{"id":"e2abfe31-044c-4950-add2-9dde133a5bcf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05426486","created_at":"2022-06-22T22:54:01.106Z","updated_at":"2025-02-25T12:28:52.301Z","phase":"Phase 2/3","brief_title":"A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients","source_id_and_acronym":"NCT05426486","lead_sponsor":"Caigang Liu","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • docetaxel • Perjeta (pertuzumab) • Irene (pyrotinib) • anvatabart opadotin (JNJ-0683)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 05/23/2022","start_date":" 05/23/2022","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2028","study_completion_date":" 12/30/2028","last_update_posted":"2024-10-30"},{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"c1d55f5b-2f1e-433d-be41-743b5f5540d8","acronym":"ACE-Breast-3","url":"https://clinicaltrials.gov/study/NCT04829604","created_at":"2021-04-02T11:53:47.301Z","updated_at":"2024-07-02T16:34:27.450Z","phase":"Phase 2","brief_title":"ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)","source_id_and_acronym":"NCT04829604 - ACE-Breast-3","lead_sponsor":"Ambrx, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • Tukysa (tucatinib) • anvatabart opadotin (JNJ-0683)"],"overall_status":"Recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 10/26/2021","start_date":" 10/26/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-06-11"},{"id":"21ff3022-c859-4f09-8f1a-345ba989a41a","acronym":"ACE-Pan Tumor-02","url":"https://clinicaltrials.gov/study/NCT05041972","created_at":"2021-09-13T14:55:49.467Z","updated_at":"2024-07-02T16:36:04.059Z","phase":"Phase 2","brief_title":"ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)","source_id_and_acronym":"NCT05041972 - ACE-Pan Tumor-02","lead_sponsor":"Ambrx, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anvatabart opadotin (JNJ-0683)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 11/05/2021","start_date":" 11/05/2021","primary_txt":" Primary completion: 04/20/2022","primary_completion_date":" 04/20/2022","study_txt":" Completion: 04/20/2022","study_completion_date":" 04/20/2022","last_update_posted":"2022-09-13"},{"id":"fe2c0b1d-f362-428b-a4f7-2c0575ef3fae","acronym":"","url":"https://clinicaltrials.gov/study/NCT04983121","created_at":"2021-07-30T18:55:10.516Z","updated_at":"2025-02-25T13:53:54.140Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients","source_id_and_acronym":"NCT04983121","lead_sponsor":"Shengjing Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Irene (pyrotinib) • anvatabart opadotin (JNJ-0683)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/01/2021","start_date":" 08/01/2021","primary_txt":" Primary completion: 08/15/2027","primary_completion_date":" 08/15/2027","study_txt":" Completion: 08/15/2027","study_completion_date":" 08/15/2027","last_update_posted":"2022-09-13"},{"id":"a08530fe-ae42-4159-ad5e-e3ada4aa47bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT05018702","created_at":"2021-08-24T11:52:58.154Z","updated_at":"2024-07-02T16:36:09.578Z","phase":"Phase 2","brief_title":"ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases","source_id_and_acronym":"NCT05018702","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anvatabart opadotin (JNJ-0683)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/14/2021","start_date":" 07/14/2021","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2022-06-01"},{"id":"689c6049-2a2f-4a74-9a8b-92d262cf6cc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05018676","created_at":"2021-08-24T11:52:57.776Z","updated_at":"2024-07-02T16:36:11.538Z","phase":"Phase 2","brief_title":"ARX788 in Breast Cancer With Low Expression of HER2","source_id_and_acronym":"NCT05018676","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HR positive • HER-2 expression • HER-2 underexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive • HER-2 expression • HER-2 underexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anvatabart opadotin (JNJ-0683)"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 10/20/2021","start_date":" 10/20/2021","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 06/30/2023","study_completion_date":" 06/30/2023","last_update_posted":"2022-04-25"},{"id":"c72d3115-3e38-49ac-aa78-f108effa2469","acronym":"ACE-Pan Tumor-02","url":"https://clinicaltrials.gov/study/NCT05023330","created_at":"2021-08-26T12:53:11.223Z","updated_at":"2025-02-26T11:52:52.484Z","phase":"Phase 2","brief_title":"ARX788 in Selected HER2-mutated or HER2-amplified Solid Tumors","source_id_and_acronym":"NCT05023330 - ACE-Pan Tumor-02","lead_sponsor":"Ambrx, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anvatabart opadotin (JNJ-0683)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2021-08-26"}]